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Introduction: The CRUK SMP2 programme was set-up to evaluate
the feasibility of performing large scale molecular analysis within the
NHS on the (often small) diagnostic biopsies obtained in NSCLC. The
results are used to allocate patients to an appropriatemolecular ther-
apy within the “umbrella” MATRIX trial. Newcastle opened SMP2 on
01/10/2014. Here we report our ﬁrst year’s experience.
Methods:NSCLC patients with PS 0–2were consented onto the CRUK
SMP2. Matched residual diagnostic tissue and blood were sent to All
Wales Genetics Laboratory, Cardiff. Samples with >70ng DNA were
assessed for 28 oncogenes using Next Genuine Sequencing on the Il-
lumina SMP2 panel.
Results: 116 patients were consented from 6/10/14–1/10/15 referred
from 12 oncologists. The data on patient/sample ﬂow is shown in Fig
1. Median survival was 161 days from consent. The 1st sample was
sent to Cardiff on 28/1/15 as the Illumina panel was undergoing ﬁ-
nal validation. 50 samples have been sent; 11 had insuﬃcient DNA;
these samples had lower cell number (but with no impact of necro-
sis/tumour proportion); The most commonly altered gene was K-Ras
(13 of 22 adenocarcinomas). Only 2 patients with results from >25
of the 28 genes had no tier 1 or 2 ie potentially treatable molecular
abnormalities. The median time from consent to result was 109 days
(range 45–250) with delays occurring throughout the pathway.
Conclusion: Patients and oncologists are keen to be involved in
molecular proﬁling; but patients need to be consented early to al-
low results to guide therapy. Prioritisation of samples is key. Not all
samples are suitable for analysis due to small cell number or low tu-
mour proportion. Molecular analysis may require extra resource in
pathology, if it is to become standard of care. The ﬁrst 4 patients to
start treatment onMATRIX were enrolled from 27/8/15 in Newcastle.
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Introduction: Brigatinib is an investigational oral tyrosine kinase in-
hibitor with preclinical activity against both rearranged ALK and clin-
ically identiﬁed crizotinib-resistant mutant ALK.
Methods: In this ongoing phase 1/2, single-arm, open-label, mul-
ticenter study in patients with advanced malignancies (N=137;
NCT01449461), patients received oral brigatinib at total doses of 30–
300 mg daily. Antitumor eﬃcacy (per RECIST v1.1) and safety data
are reported in ALK+ NSCLC and all patients, respectively.
Results: Median age of ALK+ NSCLC patients (n=79) was 54 (29–83)
years, 49%were female, 90% received prior crizotinib, and 47% had≥2
prior chemotherapy regimens. As of February 17, 2015, 45/79 (57%)
remained on study; median time on treatment was 12.6 months (1
day to 35.5months). Evaluable ALK+ NSCLC patients had ORR/median
PFS of 74%/13.4 months (Table). A post hoc independent radiologi-
cal review of patients with brain metastases at baseline showed (as
of February 9, 2015): 8/15 (53%) patients with measurable brain le-
sions ≥10 mm had an intracranial response; 11/31 (35%) patients
with only nonmeasurable lesions had disappearance of all lesions.
Treatment-emergent AEs in ≥30% of total patients (N=137), gener-
ally grades 1/2, included nausea (52%), fatigue (42%), diarrhea (40%),
headache (33%), and cough (32%); serious AEs in ≥2% of all patients,
regardless of attribution, included dyspnea (7%), pneumonia (6%), hy-
poxia (5%), pulmonary embolism (3%), and pyrexia (2%).
Conclusion: Brigatinib had antitumor activity in ALK+ NSCLC pa-
tients with (71% ORR; median PFS, 13.4 months) or without (100%
ORR) prior crizotinib, including patients with brain metastases (53%
ORR, measurable brain lesions). A pivotal, randomized, phase 2 trial
of brigatinib in patients with crizotinib-resistant ALK+ NSCLC is on-
